Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maurice Gatera.
The Lancet | 2014
Agnes Binagwaho; Paul Farmer; Sabin Nsanzimana; Corine Karema; Michel Gasana; Jean de Dieu Ngirabega; Fidele Ngabo; Claire M. Wagner; Cameron T Nutt; Thierry Nyatanyi; Maurice Gatera; Yvonne Kayiteshonga; Cathy Mugeni; Placidie Mugwaneza; Joseph Shema; Parfait Uwaliraye; Erick Gaju; Marie Aimee Muhimpundu; Theophile Dushime; Florent Senyana; Jean Baptiste Mazarati; Celsa Muzayire Gaju; Lisine Tuyisenge; Vincent Mutabazi; Patrick Kyamanywa; Vincent Rusanganwa; Jean Pierre Nyemazi; Agathe Umutoni; Ida Kankindi; Christian R Ntizimira
Two decades ago, the genocide against the Tutsis in Rwanda led to the deaths of 1 million people, and the displacement of millions more. Injury and trauma were followed by the effects of a devastated health system and economy. In the years that followed, a new course set by a new government set into motion equity-oriented national policies focusing on social cohesion and people-centred development. Premature mortality rates have fallen precipitously in recent years, and life expectancy has doubled since the mid-1990s. Here we reflect on the lessons learned in rebuilding Rwandas health sector during the past two decades, as the country now prepares itself to take on new challenges in health-care delivery.
The Lancet Global Health | 2016
Fidele Ngabo; Jacqueline E. Tate; Maurice Gatera; Celse Rugambwa; Philippe Donnen; Philippe Lepage; Jason M. Mwenda; Agnes Binagwaho; Umesh D. Parashar
BACKGROUND In May, 2012, Rwanda became the first low-income African country to introduce pentavalent rotavirus vaccine into its routine national immunisation programme. Although the potential health benefits of rotavirus vaccination are huge in low-income African countries that account for more than half the global deaths from rotavirus, concerns remain about the performance of oral rotavirus vaccines in these challenging settings. METHODS We conducted a time-series analysis to examine trends in admissions to hospital for non-bloody diarrhoea in children younger than 5 years in Rwanda between Jan 1, 2009, and Dec 31, 2014, using monthly discharge data from the Health Management Information System. Additionally, we reviewed the registries in the paediatric wards at six hospitals from 2009 to 2014 and abstracted the number of total admissions and admissions for diarrhoea in children younger than 5 years by admission month and age group. We studied trends in admissions specific to rotavirus at one hospital that had undertaken active rotavirus surveillance from 2011 to 2014. We assessed changes in rotavirus epidemiology by use of data from eight active surveillance hospitals. FINDINGS Compared with the 2009-11 prevaccine baseline, hospital admissions for non-bloody diarrhoea captured by the Health Management Information System fell by 17-29% from a pre-vaccine median of 4051 to 2881 in 2013 and 3371 in 2014, admissions for acute gastroenteritis captured in paediatric ward registries decreased by 48-49%, and admissions specific to rotavirus captured by active surveillance fell by 61-70%. The greatest effect was recorded in children age-eligible to be vaccinated, but we noted a decrease in the proportion of children with diarrhoea testing positive for rotavirus in almost every age group. INTERPRETATION The number of admissions to hospital for diarrhoea and rotavirus in Rwanda fell substantially after rotavirus vaccine implementation, including among older children age-ineligible for vaccination, suggesting indirect protection through reduced transmission of rotavirus. These data highlight the benefits of routine vaccination against rotavirus in low-income settings. FUNDING Gavi, the Vaccine Alliance and the Government of Rwanda.
Clinical Infectious Diseases | 2016
Jacqueline E. Tate; Fidele Ngabo; Philippe Donnen; Maurice Gatera; Jeannine Uwimana; Celse Rugambwa; Jason M. Mwenda; Umesh D. Parashar
BACKGROUND Rotavirus vaccine efficacy is lower in low-income countries than in high-income countries. Rwanda was one of the first low-income countries in sub-Saharan Africa to introduce rotavirus vaccine into its national immunization program. We sought to evaluate rotavirus vaccine effectiveness (VE) in this setting. METHODS VE was assessed using a case-control design. Cases and test-negative controls were children who presented with a diarrheal illness to 1 of 8 sentinel district hospitals and 10 associated health centers and had a stool specimen that tested positive (cases) or negative (controls) for rotavirus by enzyme immunoassay. Due to high vaccine coverage almost immediately after vaccine introduction, the analysis was restricted to children 7-18 weeks of age at time of rotavirus vaccine introduction. VE was calculated as (1 - odds ratio) × 100, where the odds ratio was the adjusted odds ratio for the rotavirus vaccination rate among case-patients compared with controls. RESULTS Forty-eight rotavirus-positive and 152 rotavirus-negative children were enrolled. Rotavirus-positive children were significantly less likely to have received rotavirus vaccine (33/44 [73%] unvaccinated) compared with rotavirus-negative children (81/136 [59%] unvaccinated) (P= .002). A full 3-dose series was 75% (95% confidence interval [CI], 31%-91%) effective against rotavirus gastroenteritis requiring hospitalization or a health center visit and was 65% (95% CI, -80% to 93%) in children 6-11 months of age and 81% (95% CI, 25%-95%) in children ≥12 months of age. CONCLUSIONS Rotavirus vaccine is effective in preventing rotavirus disease in Rwandan children who began their rotavirus vaccine series from 7 to 18 weeks of age. Protection from vaccination was sustained after the first year of life.
Vaccine | 2015
Fidele Ngabo; Ann Levin; Susan S.A. Wang; Maurice Gatera; Celse Rugambwa; Celestin Kayonga; Philippe Donnen; Philippe Lepage; Raymond Hutubessy
Background Detailed cost evaluations of delivery of new vaccines such as pneumococcal conjugate, human papillomavirus (HPV), and rotavirus vaccines in low and middle-income countries are scarce. This paper differs from others by comparing the costs of introducing multiple vaccines in a single country and then assessing the financial and economic impact at the time and implications for the future. The objective of the analysis was to understand the introduction and delivery cost per dose or per child of the three new vaccines in Rwanda to inform domestic and external financial resource mobilization. Methods Start-up, recurrent, and capital costs from a government perspective were collected in 2012. Since pneumococcal conjugate and HPV vaccines had already been introduced, cost data for those vaccines were collected retrospectively while prospective (projected) costing was done for rotavirus vaccine. Results The financial unit cost per fully immunized child (or girl for HPV vaccine) of delivering 3 doses of each vaccine (without costs related to vaccine procurement) was
PLOS ONE | 2016
Fidele Ngabo; Mercy Mvundura; Lauren Gazley; Maurice Gatera; Celse Rugambwa; Eugene Kayonga; Yvette Tuyishime; Jeanne Niyibaho; Jason M. Mwenda; Philippe Donnen; Philippe Lepage; Agnes Binagwaho; Deborah Atherly
0.37 for rotavirus (RotaTeq®) vaccine,
International Journal of Cancer | 2016
Silvia Franceschi; M. Chantal Umulisa; Ugyen Tshomo; Tarik Gheit; Iacopo Baussano; Vanessa Tenet; Tshokey Tshokey; Maurice Gatera; Fidele Ngabo; Pierre Van Damme; Peter J.F. Snijders; Massimo Tommasino; Alex Vorsters; Gary M. Clifford
0.54 for pneumococcal (Prevnar®) vaccine in pre-filled syringes, and
Vaccine | 2016
Maurice Gatera; Sunil Bhatt; Fidele Ngabo; Mathilde Utamuliza; Hassan Sibomana; Corine Karema; Cathy Mugeni; Cameron T Nutt; Sabin Nsanzimana; Claire M. Wagner; Agnes Binagwaho
10.23 for HPV (Gardasil ®) vaccine. The financial delivery costs of Prevnar® and RotaTeq® were similar since both were delivered using existing health system infrastructure to deliver infant vaccines at health centers. The total financial cost of delivering Gardasil® was higher than those of the two infant vaccines due to greater resource requirements associated with creating a new vaccine delivery system in for a new target population of 12-year-old girls who have not previously been served by the existing routine infant immunization program. Conclusion The analysis indicates that service delivery strategies have an important influence on costs of introducing new vaccines and costs per girl reached with HPV vaccine are higher than the other two vaccines because of its delivery strategy. Documented information on financial commitments for new vaccines, particularly from government sources, is a useful input into country policy dialogue on sustainable financing and co-financing of new vaccines, as well as for policy decisions by donors such as Gavi, the Vaccine Alliance.
Pediatric Infectious Disease Journal | 2014
Fidele Ngabo; Maurice Gatera; Corinne Karema; Philippe Donnen; Philippe Lepage; Umesh D. Parashar; Jacqueline E. Tate; Jason M. Mwenda; Celse Rugambwa; Agnes Binagwaho
Background Diarrhea is one of the leading causes of childhood morbidity and mortality. Hospitalization for diarrhea can pose a significant burden to health systems and households. The objective of this study was to estimate the economic burden attributable to hospitalization for diarrhea among children less than five years old in Rwanda. These data can be used by decision-makers to assess the impact of interventions that reduce diarrhea morbidity, including rotavirus vaccine introduction. Methods This was a prospective costing study where medical records and hospital bills for children admitted with diarrhea at three hospitals were collected to estimate resource use and costs. Hospital length of stay was calculated from medical records. Costs incurred during the hospitalization were abstracted from the hospital bills. Interviews with the child’s caregivers provided data to estimate household costs which included transport costs and lost income. The portion of medical costs borne by insurance and household were reported separately. Annual economic burden before and after rotavirus vaccine introduction was estimated by multiplying the reported number of diarrhea hospitalizations in public health centers and district hospitals by the estimated economic burden per hospitalization. All costs are presented in 2014 US
Vaccine | 2016
Maurice Gatera; Jeannine Uwimana; Emmanuel Manzi; Fidele Ngabo; Friday Nwaigwe; Bradford D. Gessner; Jennifer C. Moïsi
. Results Costs for 203 children were analyzed. Approximately 93% of the children had health insurance coverage. Average hospital length of stay was 5.3 ± 3.9 days. Average medical costs for each child for the illness resulting in a hospitalization were
The Lancet | 2013
Agnes Binagwaho; Fidele Ngabo; Cathy Mugeni; Corine Karema; Maurice Gatera; Cameron T Nutt; Claire M. Wagner; Mary Dain; Jean Pierre Nyemazi
44.22 ±